Jumeau Raphael, Vilotte Florent, Durham André-Dante, Ozsahin Esat-Mahmut
Department of Radiation-Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S192-S201. doi: 10.21037/tlcr.2019.08.10.
Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent.
放射治疗（RT）是晚期III期和IV期非小细胞肺癌（NSCLC）患者治疗的基石。尽管有国际指南，但临床实践仍然存在差异。此外，立体定向消融放疗（SABR）的出现以及免疫疗法等新的全身治疗方法动摇了这些患者治疗方法中的传统观念。本综述将重点关注NSCLC的姑息性胸部放疗，但也将讨论立体定向放疗、支气管内近距离放疗（EBB）的作用、联合治疗（化疗和免疫疗法）的意义以及具有姑息意图的放疗在肺癌急症中的作用。
